A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

NCT03731182 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: V114
BIOLOGICAL: Prevnar 13™

Sponsor

Merck Sharp & Dohme LLC